| Document |
Document Title |
|
WO/2024/050998A1 |
Disclosed are a nucleic acid detection reagent for rapidly detecting a pathogen of pets, and a kit and a use thereof. Specifically, the method comprises: step T1, lysing, in a constant-temperature environment, a sample to be detected; st...
|
|
WO/2024/054823A1 |
Disclosed herein include methods, compositions, and kits for monitoring an amplification reaction. Some embodiments include a quality control template comprising a 5' subdomain, a 3' subdomain, and a loop domain situated between the 5' s...
|
|
WO/2023/230617A9 |
Compositions, kits, and methods for the prognosis of bladder cancer in a subject are provided by detecting in tumor tissue a combination of biomarkers consisting of ANG, A1AT, APOE, CA9, IL8, MMP9, MMP10, PAI-1, SDC1 and VEFGA.
|
|
WO/2024/054739A1 |
Disclosed is a blood contamination detection apparatus. The blood contamination detection apparatus comprises a computer-based contamination determining module configured to receive: one or more baseline quantified test results on an unc...
|
|
WO/2024/054941A1 |
SARS-CoV-2 has caused a global pandemic with significant humanity and economic loss since the beginning of 2020. Flaviviruses such as Zika and Dengue viruses are also significant human pathogens. Although SARS-CoV-2 vaccines are effectiv...
|
|
WO/2024/053933A1 |
Unlike DNA, mRNA has the advantage of enabling transient expression of a desired protein directly in the cytoplasm without having to enter the nucleus, and thus, attempts to use mRNA vaccines are actively underway. However, mRNA has lowe...
|
|
WO/2024/053742A1 |
The present invention provides a pharmaceutical composition that comprises an IL-10 inhibitor and that is for use in the treatment or prevention of novel coronavirus (SARS-CoV-2) infection (COVID-19).
|
|
WO/2024/052738A1 |
The present invention discloses a multi-parametric method for identification, quantification and in-vivo response as sessment of viable microbial organisms from biological specimens. Said method utilizes live media for the first few cycl...
|
|
WO/2024/054372A1 |
Disclosed are compositions, uses of the compositions, methods of treatment, methods of modulating enzyme activity, methods of sequestering a target molecule, methods of delivering an enzyme, and methods of prophylaxis. In particular, the...
|
|
WO/2024/054627A1 |
Living tissue substrates (LTSs) are provided for diagnosing a tumor or screening for a therapeutic for a tumor are provided. Methods and systems for diagnosing a tumor or screening for a therapeutic for a tumor are provided, and can incl...
|
|
WO/2024/053642A1 |
According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific...
|
|
WO/2023/077029A9 |
The invention provides single-cell analysis using combined DNA sequencing of genomic DNA, which is performed to determine whether a segment of foreign DNA has been integrated. Individual cells are encapsulated with reagents, including pr...
|
|
WO/2024/054924A1 |
Provided are compositions, kits, and methods that can be used to selectively amplify a first target nucleic acid that is distinguishable from a second target nucleic acid, where the two target nucleic acids have both common and different...
|
|
WO/2024/052630A1 |
The present invention relates to a method for in vitro or ex vivo detection of an immunocompromised status in a subject, comprising quantifying, in a biological sample of said subject, the expression of at least 2 target genes selected f...
|
|
WO/2024/053919A1 |
The present invention provides a composition for diagnosing diabetic retinopathy using a biomarker, a method for providing information for diagnosing diabetic retinopathy, and a method for screening a material for treating diabetic retin...
|
|
WO/2024/054087A1 |
The present invention relates to a biomarker for diagnosing infertility in elderly women and a use thereof, and can not only non-invasively diagnose infertility in elderly women, but can also be a useful new target for infertility treatm...
|
|
WO/2024/054313A1 |
The present disclosure describes a computer implemented method, a system, and a computer program product of measuring quality attributes of a virus sample. In an embodiment, the method, system, and computer program product include (1) re...
|
|
WO/2024/053191A1 |
Provided are a test container and a nucleic acid test method using the test container, wherein: a sample container is provided with an inlet into which a sample liquid is introduced, a liquid holding part, a pretreatment chamber, a valve...
|
|
WO/2024/050820A1 |
An antioxidant composition and the use thereof in nucleic acid detection. The present invention relates to an antioxidant composition, a reagent containing the composition, a kit containing the composition or reagent, the use of the comp...
|
|
WO/2024/052258A1 |
The present invention involves methods for the ex-vivo diagnosis of prostate cancer comprising the steps of i) providing a sample from a patient suspected of having prostate cancer and ii) analysing the expression level of at least one n...
|
|
WO/2024/054455A1 |
Devices for performing growth detection, identification and antimicrobial susceptibility testing (AST) functions in connection with a microbial species to achieve sample-to-answer results are disclosed. Methods of performing microbial gr...
|
|
WO/2024/052233A1 |
The present invention relates to methods for determining or predicting if a patient having a predetermined disease, for example cancer, in particular metastatic melanoma, is responsive, or will respond to a treatment based on immune chec...
|
|
WO/2024/050761A1 |
The present invention provides a PCR marker for detecting an exogenous radish fragment in a Brassica oleracea-radish introgression line, comprising one or more of PCR markers BoRa1-BoRa26. The nucleotide sequences of the BoRa1-BoRa26 are...
|
|
WO/2024/054184A1 |
The invention relates to a method for determining the microbial load in the wet wipes and identifying the source of the microbial load by the use of a wet wipe in the form of a finished product. Owing to the invention, all the microbial ...
|
|
WO/2024/050638A1 |
Provided herein compositions and methods including bioprinted tissue fibers comprising precisely patterned cancerous and non-cancerous cells that are capable of recapitulating a desired tumor microenvironment in vitro. The subject tissue...
|
|
WO/2024/053190A1 |
In a test container and a nucleic acid test method using a test container, the test container is provided with: an input port through which a sample solution is input; a liquid reservoir section; a heating chamber; a connection port thro...
|
|
WO/2024/054951A1 |
Provided includes methods, compositions and kits for improving outcome of a treatment for colorectal cancer, and methods, compositions and kits for determining responsiveness of a subject to a treatment for colorectal cancer. Determining...
|
|
WO/2024/054867A1 |
Disclosed herein include methods, compositions, and kits for use in detecting a target nucleic acid sequence in a sample. The method can comprise the use of a signal-generating oligonucleotide capable of hybridizing to a nucleic acid amp...
|
|
WO/2024/054989A1 |
Provided herein are biomarkers that may be used to identify a cancer that is susceptible to treatment with Seneca Valley Virus (SVV) or SVV derivative. The disclosure also relates to in vitro screening methods for cancers that are suscep...
|
|
WO/2024/053826A1 |
The present invention relates to: a biomarker composition for diagnosing aging which can be utilized as a biomarker for diagnosing aging by identifying the expression level of a mitoribosome protein; and a use thereof. The mitoribosome p...
|
|
WO/2024/054768A2 |
This disclosure concerns methods and compositions for identifying plants that have an Ogura CMS restorer of fertility phenotype. Some aspects concern a zygosity assay to identify, select, and/or construct Ogura CMS restorer of fertility ...
|
|
WO/2024/052948A1 |
Provided is a method for detecting pancreatic cancer by analyzing a gene of which the expression varies in association with pancreatic cancer and measuring CA19-9 in a biological sample. A method for assisting in the detection of pancr...
|
|
WO/2024/052650A1 |
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prog...
|
|
WO/2024/054564A2 |
MicroOrganoSpheres (MOS) generated using cells from multiple myeloma bone marrow biopsies are provided herein, as are methods and materials for making and using such MOS.
|
|
WO/2024/053921A1 |
The present invention provides a learning method for a prime editing efficiency prediction model of pegRNA for various cell types and various kinds of prime editors, and a method and device for predicting prime editing efficiency using t...
|
|
WO/2024/054521A1 |
Provided herein are methods and compositions for identifying α-synuclein aggregation inhibitors. Also provided are methods of use of the α -synuclein aggregation inhibitors; the methods include methods of inhibition the formation of Le...
|
|
WO/2024/052905A1 |
Methods of designing a synthetic RNA molecule comprising obtaining a coding sequence encoding a protein of interest; obtaining a sequence of an RNA expressed in a first tissue or cell type and not expressed or lowly expressed in a second...
|
|
WO/2024/054272A2 |
Techniques are describing for designing and operating a quantum oscillator. In contrast with conventional approaches to operating a quantum oscillator, the present techniques relate to an oscillator design that has less bare nonlinearity...
|
|
WO/2024/052917A1 |
Methods of treating cancer comprising reducing expression or function of eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1) or EIF4EBP2 in a cell of the cancer, wherein the function is binding Eukaryotic translation initiation ...
|
|
WO/2024/051910A2 |
|
|
WO/2024/052329A1 |
The invention concerns a method for determining the existence of or susceptibility to panic based upon the presence of serum sortilin related VPS10 domain containing receptor 3 (SORCS3); a kit for performing the afore method(s); at least...
|
|
WO/2024/053519A1 |
Disclosed are a kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease that use EDIL3 or a nucleic acid that encodes EDIL3 as an indicator or a target.
|
|
WO/2024/054572A1 |
The present disclosure is directed to methods of using salivary exosomes to detect and treat Sjögren's syndrome in a subject.
|
|
WO/2024/050817A1 |
Use of glycyrrhizic acid or a derivative thereof in nucleic acid detection. In particular, the present invention relates to a reagent comprising glycyrrhizic acid or a derivative thereof, use of glycyrrhizic acid or a derivative thereof ...
|
|
WO/2024/054946A1 |
Described herein are methods for identifying a biological state such as pancreatic cancer in a subject. For example, a method may include obtaining protein data, transcriptomic data, genomic data, lipidomic data, or metabolomic data of a...
|
|
WO/2024/054898A1 |
Disclosed herein include methods, compositions, and kits suitable for use in treating cancer in a subject. In some embodiments, the method comprises administration of onvansertib and a PART inhibitor (e.g., olaparib, niraparib, and AZD53...
|
|
WO/2024/055019A1 |
Provided are methods and systems for detection of oral bacteria.
|
|
WO/2024/050860A1 |
The present invention relates to the technical field of medical biology, and particularly, to use of RUNX2 as a marker in preparing a diagnosis or detection reagent for a malignant phyllodes tumor. The detection reagent can assist in, ac...
|
|
WO/2024/051832A1 |
Disclosed in the present invention is a method for detecting the proportion of mRNA with a polyA tail in a mRNA product. The method comprises the following steps: 1) obtaining an RNA with an adapter at the 3' end; 2) performing reverse t...
|
|
WO/2024/054662A2 |
Atomic force microscopy (AFM) can be used to image biological samples with low nanomolar resolution. Compared to other imaging modalities with nanoscale resolution, AFM does not require the use of complex, costly instrumentation or toxic...
|
